Stock Events

Stock Events

Aldeyra Therapeutics 

€1.37
61
+€0.05+3.86% Monday 06:03

Statistics

Day High
1.37
Day Low
1.37
52W High
5
52W Low
1.06
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31JulExpected
Q4 2025
Next
Next
-0.12
-0.11
-0.1
-0.08
Expected EPS
-0.11520765000000001
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 137.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is involved in creating treatments for inflammatory and autoimmune diseases, directly competing with Aldeyra's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals develops therapies for eye diseases, inflammation, and other areas, overlapping with Aldeyra's therapeutic targets.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie works on immunology and inflammatory diseases, competing in the same therapeutic areas as Aldeyra.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on treatments for inflammatory diseases and other serious illnesses, making it a competitor in Aldeyra's market.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a portfolio that includes treatments for inflammatory and respiratory diseases, areas Aldeyra is also targeting.
Biogen
BIIB
Mkt Cap27.62B
Biogen develops therapies for neurological and autoimmune diseases, competing with Aldeyra in the autoimmune space.
Adma Biologics
ADMA
Mkt Cap2.44B
ADMA Biologics is involved in the development of treatments for immune disorders, overlapping with Aldeyra's focus on immune-mediated diseases.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation focuses on oncology and inflammation, directly competing with Aldeyra in the development of treatments for inflammatory diseases.

About

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Show more...
CEO
Dr. Todd C. Brady M.D., Ph.D.
Employees
8
Country
United States
ISIN
US01438T1060

Listings

F
DE
137.F
MU
DE
137.MU
STU
DE
137.STU
XNAS
US
ALDX

0 Comments

Share your thoughts

FAQ

What is Aldeyra Therapeutics stock price today?▼
The current price of 137.MU is €1.37 EUR — it has increased by +3.86% in the past 24 hours. Watch Aldeyra Therapeutics stock price performance more closely on the chart.
What is Aldeyra Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aldeyra Therapeutics stocks are traded under the ticker 137.MU.
Is Aldeyra Therapeutics stock price growing?▼
137.MU stock has risen by +0.16% compared to the previous week, the month change is a -11.12% fall, over the last year Aldeyra Therapeutics has showed a -43.76% decrease.
When is the next Aldeyra Therapeutics earnings date?▼
Aldeyra Therapeutics is going to release the next earnings report on July 31, 2026.
How many employees does Aldeyra Therapeutics have?▼
As of May 06, 2026, the company has 8 employees.
In which sector is Aldeyra Therapeutics located?▼
Aldeyra Therapeutics operates in the Health & Wellness sector.
When did Aldeyra Therapeutics complete a stock split?▼
Aldeyra Therapeutics has not had any recent stock splits.
Where is Aldeyra Therapeutics headquartered?▼
Aldeyra Therapeutics is headquartered in Lexington, United States.